Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + TSEB in MF/SS
NCT02822586Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brentuximab vedotin in mycosis fungoides (MF) and Sézary syndrome (SS) (2 cohorts), sponsored by Virginia Commonwealth University. Primary endpoints: Cutaneous Toxicity at 6 months and Objective Response Rate at 2 years. Started Dec 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT02822586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822586.